173 related articles for article (PubMed ID: 36179985)
21. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler A; Labopin M; Dholaria B; Ciceri F; Fraccaroli A; Blaise D; Fanin R; Bruno B; Forcade E; Vydra J; Chevallier P; Bulabois CE; Jindra P; Bornhäuser M; Canaani J; Sanz J; Savani BN; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M
Transplant Cell Ther; 2022 Nov; 28(11):773.e1-773.e8. PubMed ID: 36031079
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
23. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
[TBL] [Abstract][Full Text] [Related]
25. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Vergara-Cadavid J; Johnson PC; Kim HT; Yi A; Sise ME; Leaf DE; Hanna PE; Ho VT; Cutler CS; Antin JH; Gooptu M; Kelkar AH; Wells SL; Nikiforow S; Koreth J; Romee R; Soiffer RJ; Shapiro RM; Gupta S
Transplant Cell Ther; 2023 Jul; 29(7):455.e1-455.e9. PubMed ID: 37015320
[TBL] [Abstract][Full Text] [Related]
26. Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Olivieri DJ; Othus M; Orvain C; Rodríguez-Arbolí E; Milano F; Sandmaier BM; Khan I; Davis C; Basom RS; Appelbaum FR; Walter RB
Leukemia; 2024 Apr; 38(4):865-876. PubMed ID: 38388647
[TBL] [Abstract][Full Text] [Related]
27. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
28. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
31. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
32. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
33. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
[TBL] [Abstract][Full Text] [Related]
34. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
Bejanyan N; Zhang M; Bo-Subait K; Brunstein C; Wang H; Warlick ED; Giralt S; Nishihori T; Martino R; Passweg J; Dias A; Copelan E; Hale G; Gale RP; Solh M; Kharfan-Dabaja MA; Diaz MA; Ganguly S; Gore S; Verdonck LF; Hossain NM; Kekre N; Savani B; Byrne M; Kanakry C; Cairo MS; Ciurea S; Schouten HC; Bredeson C; Munker R; Lazarus H; Cahn JY; van Der Poel M; Rizzieri D; Yared JA; Freytes C; Cerny J; Aljurf M; Palmisiano ND; Pawarode A; Bacher VU; Grunwald MR; Nathan S; Wirk B; Hildebrandt GC; Seo S; Olsson RF; George B; de Lima M; Hourigan CS; Sandmaier BM; Litzow M; Kebriaei P; Saber W; Weisdorf D
Transplant Cell Ther; 2021 Jan; 27(1):68.e1-68.e9. PubMed ID: 33010430
[TBL] [Abstract][Full Text] [Related]
35. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
Aljasem HA; Messner HA; Lipton JH; Kim DDH; Viswabandya A; Thyagu S; Deotare U; Michelis FV
Eur J Haematol; 2018 Mar; 100(3):308-314. PubMed ID: 29240253
[TBL] [Abstract][Full Text] [Related]
36. Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
Zarling LC; Othus M; Sandmaier BM; Milano F; Schoch G; Davis C; Bleakley M; Deeg HJ; Appelbaum FR; Storb R; Walter RB
Leukemia; 2022 Jun; 36(6):1563-1574. PubMed ID: 35440690
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
Konuma T; Mizuno S; Kondo T; Yamaguchi H; Fukuda T; Uchida N; Najima Y; Kanamori H; Ota S; Nakamae H; Nakamae M; Mizuno I; Sugita J; Onishi Y; Yokota A; Takahashi S; Kanda Y; Ichinohe T; Atsuta Y; Yano S;
Ann Hematol; 2018 Nov; 97(11):2173-2183. PubMed ID: 29978286
[TBL] [Abstract][Full Text] [Related]
38. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB
Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
Weisdorf DJ; Millard HR; Horowitz MM; Hyare PS; Champlin R; Ho V; Mielcarek M; Rezvani A; Stockerl-Goldstein K; Khoury HJ; De Lima M; Saber W; Sandmaier B; Zhang MJ; Eapen M
Cancer; 2017 Jun; 123(11):2025-2034. PubMed ID: 28117884
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Gupta V; Kim S; Hu ZH; Liu Y; Aljurf M; Bacher U; Beitinjaneh A; Cahn JY; Cerny J; Copelan E; Gadalla SM; Gale RP; Ganguly S; George B; Gerds AT; Gergis U; Hamilton BK; Hashmi S; Hildebrandt GC; Kamble RT; Kindwall-Keller T; Lazarus HM; Liesveld JL; Litzow M; Maziarz RT; Nishihori T; Olsson RF; Rizzieri D; Savani BN; Seo S; Solh M; Szer J; Verdonck LF; Wirk B; Woolfrey A; Yared JA; Alyea EP; Popat UR; Sobecks RM; Scott BL; Nakamura R; Saber W
Blood Adv; 2020 Oct; 4(19):4748-4757. PubMed ID: 33007075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
